The long non-coding RNA LUCAT1 is a negative feedback regulator of interferon responses in humans

Shiuli Agarwal, Tim Vierbuchen, Sreya Ghosh, Jennie Chan, Zhaozhao Jiang, Richard K. Kandasamy, Emiliano Ricci & Katherine A. Fitzgerald

Long non-coding RNAs are important regulators of biological processes including immune responses. The immunoregulatory functions of IncRNAs have been revealed primarily in murine models with limited understanding of IncRNAs in human immune responses. Here, we identify IncRNA LUCAT1 which is upregulated in human myeloid cells stimulated with lipopolysaccharide and other innate immune stimuli. Targeted deletion of LUCAT1 in myeloid cells increases expression of type I interferon stimulated genes in response to LPS. By contrast, increased LUCAT1 expression results in a reduction of the inducible ISG response. In activated cells, LUCAT1 is enriched in the nucleus where it associates with chromatin. Further, LUCAT1 limits transcription of interferon stimulated genes by interacting with STAT1 in the nucleus. Together, our study highlights the role of the IncRNA LUCAT1 as a post-induction feedback regulator which functions to restrain the immune response in human cells.
Type-I Interferon (IFN-α/β) production and signaling is instrumental for effective anti-viral immunity. The type I IFN response is initiated upon recognition of pathogen-associated molecular patterns (PAMPs) such as viral nucleic acids or lipopolysaccharide (LPS). The main transcription factors that induce the production of IFN-α/β are the interferon regulatory factor 3 (IRF3) and IRF7. Interferons themselves are potent cytokines that induce the expression of hundreds of interferon-stimulated genes (ISGs) in an auto- and paracrine manner through binding to the heterodimeric interferon receptor (IFNAR). ISGs interfere with viral replication and support pathogen clearance. The activation of IFN-α/β signaling is tightly regulated through the JAK-STAT1 signaling pathway and dysregulation of this signaling pathway can lead to persistent inflammation and autoimmune diseases such as lupus

While the importance of numerous protein players in these pathways has been well elucidated, the role of non-coding RNAs (ncRNAs) in the regulation of the IFN response is less well understood. Amongst the various classes of ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most widely studied in biological processes including host–pathogen interactions.

With over 17,000 lncRNAs encoded by the human genome, this group constitutes the largest class of ncRNAs and represents a large portion of human genes (Gencode v32). Arbitrarily described as greater than 200 bp in length and lacking protein-coding capacity, lncRNAs have been shown to modulate transcription, translation, and post-transcriptional processing of mRNAs in a species- and tissue-specific manner. lncRNAs can either act in cis to alter the expression of neighboring genes or act in trans and execute various functions throughout the cell. These ncRNAs can exhibit diverse roles in cellular and developmental processes but also in diseases such as cancer, autoimmunity, and cardiovascular disease. A limited number of lncRNAs have been discovered and characterized as immune regulators including IncRNA-COX2, THRIL, IncRNA-EPS, and Morribid. The molecular mechanisms that underlie the immunoregulatory functions for these RNA are diverse. For example, IncRNA-COX2 and THRIL are nuclear lncRNAs that form complexes with heterogenous nuclear ribonucleoproteins (hnRNPs) to alter the expression of target genes. Neat1 translocates to the cytoplasm to promote inflammasome assembly and stabilize Caspase-1, an inflammatory caspase that plays a pivotal role in tumorigenesis by promoting cell migration and metastasis. Furthermore, LuCAT1 was shown to be highly upregulated in retinal Muller glial cells upon Toxoplasma gondii infection indicating a potential role in host–pathogen interactions. However, very little is known about how LuCAT1 influences immune responses in human cells.

In this study, we utilize high-throughput RNA sequencing on LPS-stimulated or virus infected human dendritic cells (DCs) and identify LuCAT1 as one of the strongest induced lncRNAs. lncRNA LuCAT1 is a dynamically regulated gene that functions as a potent regulator of the IFN-α/β response. Genetic ablation of LuCAT1 using virus-like particles loaded with Cas9 and sgRNA, so-called Nanoblades, results in hyperactivation of ISGs and proinflammatory cytokines in the human monocytic cell line THP-1 as well as in primary human DCs following LPS stimulation. Accordingly, overexpression of LuCAT1 in THP-1 cells using CRISPR activation (CRISPRa) attenuates the inducible IFN-α/β response. We show that LuCAT1 interacts with STAT1 in the nucleus and in doing so restrains ISG expression. The induction of LuCAT1 is therefore a post-induction feedback regulatory mechanism to limit the magnitude and duration of the IFN-α/β response.

Results

LuCAT1 is an inducible lncRNA in activated primary human cells. To assess lncRNA expression, we performed RNA sequencing in primary human monocyte-derived dendritic cells (hMDDC) stimulated with LPS, herpes simple virus 1 (HSV-1), and influenza A virus (IAV) for 2 and 6 h. RNA sequencing data from these cells revealed differential expression of several non-coding transcripts many of which were induced in a ligand-specific manner (Fig. 1a). Amongst these lncRNAs was a previously described lncRNA, LuCAT1, which showed significant increase in expression after stimulation with all three ligands (Supplementary Fig 1a). LuCAT1 reaches the maximum induction as early as 2 h post LPS stimulation (Fig. 1b). We also employed RT-qPCR to validate these findings, which showed rapid and significant LPS-induced expression of LuCAT1 at 2 h in primary human CD14 + monocytes, DCs, and macrophages (Fig. 1c). RT-qPCR analysis of LuCAT1 expression also showed significant induction with IAV and HSV-1 in a time-dependent manner in hMDDC (Supplementary Fig 1b). Additionally, the human monocytic cell lines THP-1 as well as BLaER1 cells, which can be transdifferentiated into a monocyte-like phenotype, also displayed significant enrichment of LuCAT1 in a time-dependent manner when stimulated with LPS (Supplementary Fig 1c, d). RT-qPCR measures levels of RNA transcripts in cells which could result from RNA transcription or alterations in the stability of RNAs. We wanted to understand the kinetics of LuCAT1 expression further and employed metabolic pulse-chase labeling of RNA using 4-thio-uridine (4SU) in LPS-stimulated hMDDCs, followed by qPCR using exon-spanning primers. By comparing labeled RNA to total RNA, we validated the kinetics of LuCAT1 induction. We observed that the mature LuCAT1 RNA was newly transcribed maximally by 2 h, consistent with the RT-qPCR analysis. The kinetics of IFN-β mRNA overlapped that of LuCAT1 (Fig. 1d). As expected, we did not observe changes in the expression of the housekeeping gene GAPDH (Fig. 1d). Absolute quantification of LuCAT1 RNA revealed that LuCAT1 is expressed at low copy numbers in resting cells but upregulated to ~ 50 copies per cell upon LPS stimulation (Fig. 1e).

In contrast to protein-coding genes, lncRNAs are expressed at lower abundance and have poorly annotated transcription start and end sites. To identify the 5′ and 3′ sequence ends of LuCAT1 transcripts, we performed Rapid Amplification of cDNA Ends (RACE) from LPS-stimulated hMDDCs. Through sequencing of the RACE products, we could identify isoforms with the predicted 5′ ends from the two LuCAT1 isoforms (NR_103548.1 and NR_103549.1) in the RefSeq database (Supplementary Fig 1e). Although none of the sequenced RACE clones yielded the 3′ end from the two RefSeq isoforms, we were able to identify a 3′ end that had been predicted by several isoforms in the Ensembl database (e.g., ENST00000648773.1). There are currently 61 different LuCAT1 isoforms annotated in Ensembl (release 99). We cloned LuCAT1 transcripts using primers specific to the 5′ and 3′ ends that have been determined by RACE as well as a 3′ primer for the longer isoform.
Fig. 1 LUCAT1 is an inducible lncRNA upregulated in activated primary human cells upon immune stimulation. a Venn diagram showing number of differentially upregulated lncRNAs in LPS, HSV-1, and IAV treated hDCs (log 2 TPM > 2). b Heatmap of lncRNAs differentially expressed non-coding RNA (log 2 TPM > 2 fold over NT, Q value < 2) following LPS, HSV-1, IAV treatment at 2 h and 6 h in hDCs. c RT-qPCR analysis for absolute copy number of LUCAT1 in LPS-stimulated hDCs (n = 3). d Pulse chase 4SU incorporation in LUCAT1, IFNβ, GAPDH and LPS-stimulated hDCs. e RT-qPCR analysis showing identified and predicted isoforms of LUCAT1 in LPS-stimulated hDCs. f Schematic showing identified and predicted isoforms of LUCAT1 in LPS-stimulated hDCs. g hDCs were pretreated with NF-κB inhibitor Bay 11 followed by LPS stimulation. RT-qPCR analysis showing LUCAT1 expression in hDCs. (n = 3, unpaired t-test) and human macrophages (Right) upon LPS stimulation (n = 2 donors; one-way ANOVA Dunnett’s multiple comparisons test). h hDCs were pretreated with JAK1 inhibitor Tofacitinib followed by LPS stimulation. RT-qPCR analysis showing LUCAT1 expression in hDCs (n = 3, one-way ANOVA Dunnett’s multiple comparisons test). i LUCAT1 isoforms we detected (Fig. 1f) which highlights the diversity of LUCAT1 isoforms found in human DCs.

Engagement of TLR4 following LPS stimulation leads to activation of MyD88-dependent and TRIF-dependent signaling pathways that culminate in the activation of NF-κB and IRF3, critical transcription factors that control expression of immune response genes and type I IFNs. To evaluate the contribution of NF-κB and the IFN-α/β pathway in the inducible expression of lncRNA LUCAT1, we used Bay11-7082, an irreversible inhibitor of the IKK kinases at the concentrations 0.1 μM and 0.3 μM, and Tofacitinib, a JAK1/JAK3 inhibitor (which would block signaling from the receptor for type I IFNs amongst other pathways) at the concentrations 0.1, 0.3, and 1 μM. hMDDCs were preincubated with these inhibitors at the indicated concentrations for 30 min and then treated with LPS for 2 h. RT-qPCR analysis showed that the inducible expression of LUCAT1 was significantly impaired using either NF-κB or JAK inhibition in a dose-dependent manner (Fig. 1g, h). The levels of IL-6, an NF-κB regulated gene

NR_103548.1. Sequencing of these clones confirmed their expression in hMDDCs. Figure 1f depicts the 14 distinct LUCAT1 isoforms we detected (Fig. 1f) which highlights the diversity of LUCAT1 isoforms found in human DCs.
were dose dependently blocked by Bay11-7082, while the levels of the ISG RSAD2 were blocked by JAK inhibition as positive controls in these assays (Supplementary Fig 1e, f). Collectively, these results indicate that LUCAT1 is induced by multiple TLR ligands and viral infection in human monocytic cells.

**LUCAT1 deficiency results in a hyper-inflammatory gene signature.** We next wanted to evaluate the possibility that LUCAT1 was a regulator of the inducible inflammatory response. Given, the challenges in generating primary human transgenic cells, we have made use of a CRISPR/Cas9-based approach, so-called Nanoblades32, to target LUCAT1 in primary human cells. Nanoblades are engineered murine leukemia VLPs loaded with Cas9/sgRNA ribonucleoproteins32. By transfecting HEK-293T cells with plasmids encoding Gag-Cas9, Gag-Pro-Pol, a single-guide RNA (sgRNA), and viral envelopes, fusogenic VLPs are produced and released in the culture medium. Human DCs were incubated with Nanoblades loaded with two sgRNAs per combination and three different groups of Nanoblades were used for targeting the genomic locus and excision of LUCAT1 (Supplementary Fig 2a). Using RT-qPCR analysis of targeted polyclonal cells we found that there was effective deletion of LUCAT1 in LPS-stimulated hMDDC in all three Nanoblade sgRNA combinations (Fig. 2a). To assess the impact of LUCAT1 deletion on the transcriptome, we used RNA sequencing to evaluate basal and LPS-inducible gene expression in LUCAT1 sufficient and deficient hMDDCs. RNA-seq analysis showed tight correlation of inflammation genes all of which were elevated in cells lacking LUCAT1 (Fig. 2b). The most differentially regulated genes included IFN-β and ISGs, as several immune and non-immune genes were unchanged between the two groups (Supplementary Fig 2d). We also validated these findings in hMDDC using RT-qPCR by measuring IFN-β (Fig. 2e) and using Nanostring to measure the expression of a panel of 50 inflammatory and IFN-stimulated genes (Supplementary Fig 2c). The Nanostring analysis showed elevated levels of IFN-β, ISGs, and inflammatory response genes in all three Nanoblade sgRNA combinations following LPS stimulation relative to NTC cells treated with LPS (Supplementary Fig 2c).

We also confirmed these findings using a different cell system. We used Nanoblades to target LUCAT1 in THP-1 cells which resulted in efficient deletion of LUCAT1 (Fig. 3a). RT-qPCR analysis of these cells showed an elevated IFN-β and CXCL10 response following LPS stimulation in LUCAT1-depleted cells when compared to NTCs (Fig. 3b, c). A similar increase was observed after Sendai Virus (SeV) infection of LUCAT1−/− THP1 cells (Supplementary Fig 3a, b). The elevated expression of IFN-β and CXCL10 mRNA was also seen at the protein level in these LUCAT1 knock out THP-1 cells as compared to control cells upon LPS stimulation (Fig. 3d). We also generated short hairpin RNA (shRNA)-expressing THP-1 cells targeting LUCAT1 RNA. THP-1 expressing shRNA showed more than 50 percent knock down of LUCAT1 (Fig. 3e). Consistent with our findings using CRISPR-based Nanoblades, we observed a large increase in expression of IFN-β and IL-6 in these cells while the inducible levels of TNF-α were comparable between cell lines (Fig. 3f–h). A heatmap showing the most differentially regulated genes measured using Nanostring is shown in (Fig. 3i). Similar studies were performed using LUCAT1 shRNA-expressing BlaER1 cells. Optimal knock down of LUCAT1 resulted in elevated IFN-β expression in BlaER1 upon LPS and Sendai virus (SeV) challenge (Supplementary Fig 3d, e).

Next, we performed gain-of-function studies to overexpress LUCAT1 from its endogenous locus. THP-1 cells expressing catalytically inactive Cas9 (dCas9) fused to the transcriptional activator VP64 were transduced with sgRNA containing viral supernatant and selected for puromycin resistance. CRISPR-mediated overexpression is enabled by recruitment of transcription coactivators to target gene loci33. Five LUCAT1 targeting sgRNA were designed within −200 bp of the transcription start site (TSS). These gRNAs led to at least a 3-fold enhancement of LUCAT1 expression in THP1 cells (Fig. 3j). When these cells were then challenged with LPS and SeV we observed a significant decrease in inducible IFN-β gene expression compared to the control sgRNA expressing cell lines (Fig. 3k, l). These results indicate that expression of LUCAT1 reduced the inducible expression of these genes.

**LUCAT1 is enriched in the nucleus and associates with chromatin.** Defining the cellular distribution of lncRNAs is crucial to understand their biological function34. A large proportion of lncRNAs are retained in the nucleus where they regulate chromatin structure and accessibility as well as transcription of target genes34,35. In order to define the localization of LUCAT1, we prepared nuclear and cytoplasmic fractions of LPS-stimulated THP-1 cells and measured LUCAT1 levels in these fractions by RT-qPCR. We observed enrichment of LUCAT1 in the nuclear compartment in LPS-treated cells (Fig. 4a). To validate and expand on these findings we next performed single-molecule RNA fluorescence in situ hybridization (smFISH) on hMDDCs which confirmed these findings. While there were low levels of LUCAT1 in cells in the absence of stimulation, the levels of LUCAT1 increased and were enriched in the nucleus upon stimulation in primary hMDDC (Fig. 4b, Supplementary Fig 4a). We observed a speckled staining pattern of LUCAT1 in the nucleus, which was significantly higher in cells treated with LPS than in resting cells (Fig. 4c). We next performed RNA immunoprecipitation (RIP) using Histone H3 antibody to determine if LUCAT1 was enriched in the chromatin fraction of cells. Indeed, histone H3 RIP followed by RT-qPCR analysis showed enrichment of lncRNA LUCAT1 following LPS stimulation. This was similar to what we found for MALAT1, a known chromatin-bound lncRNA36 (Fig. 4d). Together, these findings clearly indicate the presence of LUCAT1 in multiple locations within the nucleus and its association with chromatin.

**LUCAT1 transcriptionally regulates cytokines by associating with STAT1.** We next wanted to understand if LUCAT1 was acting to alter transcription of IFN-β and ISGs. We performed Chromatin Immunoprecipitation (ChIP) followed by qPCR to assess the recruitment of RNA polymerase II (RNA pol II) and H3K4 trimethylation, a marker of active transcription at target gene loci. The recruitment of RNA pol II to the promoters of the IFN-β and RSAD2 genes was significantly enhanced in cells stimulated with LPS (Fig. 5a, b). When LUCAT1 levels were reduced by shRNA, there was increased RNA pol II binding at the promoters of both IFN-β and RSAD2 genes compared to control cells indicating that the increased expression of IFN-β and ISGs was likely due to increased transcription of these target genes. Similarly, there was an increase in H3K4me3 observed at the promoter of IFN-β and RSAD2 in LUCAT1-deficient cells in both untreated and LPS-stimulated conditions (Fig. 5c, d).
Fig. 2 LUCAT1 deficiency leads to hyperactivation of an inflammatory and ISG signature. Nanoblades were used to generate LUCAT1-deficient hDCs using three combinations of sgRNA; Nano1 (N1), Nano2 (N2), and Nano3 (N3). a RT-qPCR analysis for LUCAT1 gene expression in hDCs upon LPS stimulation in control, N1, N2, and N3 (n = 3, biologically independent experiments with 3 different donors, one-way ANOVA Dunnett’s multiple comparisons test). b Gene Ontology analysis showing enrichment of immune pathways in Nanoblade-mediated LUCAT1 depleted hDCs in LPS-stimulated conditions. Unbiased RNA sequencing was performed in Nano1, Nano2, Nano3, and NTC hDCs. c Scatterplot analysis showing differentially regulated genes in FPKM values LUCAT1 Nanoblade hDCs compared to NTC controls in LPS-stimulated conditions. d Bar graph representation of top proinflammatory genes (in FPKM) differentially regulated between Nanoblade-targeted LUCAT1 hDCs and NTC controls in LPS-stimulated conditions. e RT-qPCR analysis of IFNβ expression in Nanoblade-mediated LUCAT1 targeting in hDC cells upon LPS stimulation (n = 3, biologically independent experiments with 3 different donors, Nano1 (N1), Nano2 (N2), and Nano3 (N3, one-way ANOVA Dunnett’s multiple comparisons test). Data in a, e is represented as mean ± SEM. Data in d is represented as mean ± SD, **P ≤ 0.01.

These observations suggest that LUCAT1 normally restrains the transcription of IFN-β and ISGs. To better understand how LUCAT1 might mediate this effect we wanted to identify protein binding partners of LUCAT1 in the chromatin fraction of cells. We performed comprehensive identification of RNA-binding proteins by mass spectrometry (ChIRP-MS) in primary hMDDCs. LPS-treated primary cells were chemically cross-linked and sonicated to achieve optimal RNA fragments. Cell lysates were then incubated with biotinylated ssDNA probes that were antisense to LUCAT1 and enriched using streptavidin beads. Proteins associated with these complexes were then identified by MS. Proteomics analysis of LPS-treated samples identified many nuclear proteins in LUCAT1 pull downs (Supplementary Data 1). Amongst these were histones as well as STAT1. To further confirm these findings, we performed RIP using STAT1 antibody. STAT1 complexes were pulled down from nuclear extracts of LPS-stimulated cells and the levels of LUCAT1 measured by RT-qPCR (Fig. 5e). In contrast to STAT1 pull downs, antibody to IRF3 or IgG had no LUCAT1 binding. Since these studies indicated that LUCAT1 associated with STAT1 we next evaluated...
if STAT1 function was altered in cells lacking LUCAT1. To this end, we evaluated STAT1 binding to the promoters of ISGs using STAT1 ChIP-qPCR in WT and LUCAT1-deficient THP1 cells stimulated with LPS (Fig. 5f–i). We observed increased occupancy of STAT1 at the promoter regions of IFI16 and MX2 in cells lacking LUCAT1. All together these results indicate that LUCAT1 associates with STAT1 in the nucleus and alters STAT1 function by reducing STAT1 binding at ISGs to modulate their transcription.

Discussion

Type I interferons are a family of cytokines which function primarily to elicit immune responses against viruses and bacteria in an autocrine, paracrine, and systemic manner. In addition, activation of type I IFNs can also lead to cellular proliferation, differentiation, and migration, all of which impact type I IFN-mediated pathogen clearance and restoration of tissue homeostasis. Although, activation of type I IFN is important for protective immunity during infection, excessive production of type I IFN leads to chronic inflammation and tissue damage as characterized by many autoimmune disorders including systemic lupus erythematosus (SLE), Sjogren’s syndrome, and Aicardi–Goutières syndrome (AGS)\textsuperscript{38,39}. Therefore, tight regulation of type I IFN responses is necessary to maintain immune homeostasis. The type I IFN response is mediated by binding of IFNa/β to the heterodimeric IFNα/β receptor (IFNAR1/IFNAR2) which results in phosphorylation of receptor-associated tyrosine kinases, tyrosine kinase 2 (TYK2), and Janus kinase 1 (JAK1). Phosphorylation of TYK2 and JAK1 in turn activate signal transducer and activators of transcription 1 (STAT1) and STAT2 by phosphorylating tyrosine residues. Phosphorylated STAT1–STAT2 heterodimers translocate to the nucleus and form an IFN-stimulated gene factor 3 complex (ISGF3) complex with IRF9\textsuperscript{2,3,40}. Binding of the ISGF3 complex to the promoters of IFN-stimulated genes (ISGs) is important for induction of these genes and effective anti-microbial responses\textsuperscript{2–4}.

JAK1-STAT1 signaling also leads to upregulation of various immunomodulatory proteins which act in a negative feedback
manner to turn off the IFN-α/β signaling. Negative regulation of the type I IFN pathway involves numerous protein factors that act to limit PRRs, PRR signaling, and as well as IFN signaling itself. Suppressor of cytokine signaling (SOCS1 and SOCS3) proteins, specifically SOCS1 is a potent negative regulator of type I IFN signaling and functions by reducing TYK2 and STAT1 phosphorylation. SOCS1 deficiency has been associated with increased ISG transcription, cytokine production, and enhanced pathogen clearance in murine models.24,25 Similarly, Src homology phosphatase proteins (SHP1 and SHP2) inhibit phosphorylation of signaling molecules including STAT1 and JAK1 to downregulate type I IFN signaling.46 Many negative regulators of type I IFN signaling bind to the receptor itself to alter signaling. USP18 is an example of one such protein that binds IFNAR1/IFNAR2 and displaces JAK1, thus altering its binding preference to low-affinity IFN-α, thereby decreasing the overall strength of type I IFN signaling.44,45 In addition to these protein regulators of the type I IFN response, a growing body of literature has identified non-coding RNAs including miRNAs and lncRNAs, that are co-expressed with ISGs. miRNAs are known to have diverse roles in immune pathways including inhibiting type I IFN signaling by targeting STAT1 and STAT2 (miRNA 221/222), suppression of IFNβ production (miRNA miR26a, miR34a, miR145, and Let7b)46, and negative regulation of PRRs such as RIG-I (miRNA-146a)47. Additionally, lncRNAs such as lncRNA-CMPK2 have been shown to downregulate IFN-α/β responses by acting in a negative feedback manner; however not many lncRNAs are known that modulate IFN-α/β responses in human cells.48

Here, we have identified LUCAT1 as a new regulator that limits the type I IFN response in human myeloid cells. High-throughput RNA sequencing revealed LUCAT1 as one the most dynamically regulated lncRNAs in HSV-1, IAV-, and LPS-stimulated hMDDCs as well as in other primary myeloid cells and cell lines. The role of LUCAT1 in regulation of type I IFN responses was further characterized by loss-of-function studies. Unbiased transcriptome analysis on LUCAT1-depleted primary hMDDCs showed an increased inflammatory gene signature that predominantly included numerous STAT1-regulated genes such as CCL5, IP10, IFIT1 and RSAD2. We also observe differential regulation of other inflammatory genes such as NF-kB-driven IL-6 and IL-10, suggesting a broader role of LUCAT1 in restraining immune responses. Additionally, we utilized CRISPRa to generate LUCAT1-overexpressing human monocytic cells. In contrast to loss-of-function studies, increased levels of LUCAT1 suppressed the expression of inflammatory genes and ISGs. A similar observation was made in a diabetic model of a human lung cell line, where overexpression of LUCAT1 led to decreased levels of iNOS and NO.49 These results provide compelling evidence that LUCAT1 regulates an anti-inflammatory program specifically by restraining the type I IFN and inflammatory response during acute phases of infection.

![Image](https://via.placeholder.com/150)
Since lncRNAs impact biological process through a diversity of mechanisms, it is informative to understand where in the cell these RNAs are localized. Cellular localization dictates regulation and function. Numerous studies have shown that nuclear localized lncRNAs modulate chromatin state, transcription, or RNA splicing, contrary to lncRNAs in the cytosol, that can localize lncRNAs modulate chromatin state, transcription, or block transcription of STAT1 target genes. ChIP analysis revealed increased STAT1 binding to the promoters of ISGs when LUCAT1 levels were limiting consistent with the sequestration model outlined above. A better understanding of these mechanisms could further enhance understanding of lncRNA LUCAT1-mediated regulatory pathway for ISG regulation.

**Methods**

**Ethics.** De-identified human blood products were obtained from the Rhode Island Blood Center. Studies with human PBMC were conducted with approval from the Institutional Review Board of the University of Massachusetts Medical School. All donors provided written informed consent. All studies were approved by the Institutional Biosafety committee at University of Massachusetts Medical School.

**Human samples.** Leukoreduction system (LRS) chambers from healthy donors were obtained from the Rhode Island Blood Center. Peripheral blood mononuclear cells (PBMC) were obtained from LRS chambers by lymphoprep density gradient centrifugation (Stemcell Technologies, Cat#07851). CD14 positive monocytes were isolated from PBMCs by magnetic cell separation (MACS) using CD14 microbeads (Miltenyi, Cat#130-050-201). Purity of isolated CD14 positive cells was determined by flow cytometry. Written informed consent was obtained from all leukocyte donors.

**Cell culture.** THP-1 cell line was obtained from ATCC (Cat#ATCC TIB-202) and maintained in RPMI 1640 (Corning, Cat#10-040-CV) supplemented with 10% FBS and 1% Pen/Strep and were differentiated into macrophages in the presence of 10 ng/ml phorbol-12-myristate acetate (PMA, Sigma, Cat#P8139) for 12–16 h followed by media change and rest for up to 48 h. CD14+ monocytes were differentiated into monocyte-derived Dendritic Cells (hMDDCs) using a cocktail of hiL-4 and hGM-CSF (produced in 293T cells) in RPMI with 10% heat-inactivated, pooled human AB serum (Sigma) for 7–8 days. CD14+ monocytes were also differentiated into monocyte-derived Macrophages (hMDMs) using hiL-CSF.
(Peprotech, Human Recombinant M-CSF, #300-25) in RPMI with 10% pooled human AB serum (Sigma) for 5–6 days. BLAER1 were obtained from Dr. Viet Harnong Laboratory, Munich, and cultured in RPMI, 10% FCS, 1% Glutamine, 1% Pen/strep. For differentiation, 10^5 cells in culture media was used in 96 well plate supplemented with 10 ng/ml of hrl-3 (PeproTech, Cat#20-003), 10 ng/ml hr-CSF-1 (M-CSF) (Peprotech, Cat#30-20-05), and 100 nM β-Estradiol (Sigma-Aldrich, Cat#E8875) and incubated for 5–6 days. Before stimulation, differentiation media was changed to culture media. CXCL10 ELISA. THP-1 wild type cells and THP-1 LUCAT1 KO cells were stimulated with LPS at 2 ng/ml and 200 ng/ml for 6 h. Supernatants were collected and diluted 1:5 in PBS + 1% BSA buffer. Cytokine levels in supernatants were measured by CXCL10 ELISA (R&D Systems, Cat#DY6266) according to the manufacturer’s instructions. Reagents. Reagents used in the study were obtained from following sources: E. coli LPS was purchased from Sigma-Aldrich (Cat#L2630); recombinant human M-CSF (Peprotech, #300-25); NF-κB inhibitor BAY-7082 (Tocris Bioscience, Cat#1744); Tofacitinib (Sigma, Cat#PZ0017), and HSV-1 (David Knipe Laboratory). Sendai virus (Cantrell strain) were purchased from Charles River Laboratories (Wilmington, MA), GeneJuce was from Millipore, #70967-6. Customized nCounter gene expression code-set was obtained from NanoString technologies (Seattle, WA). RNA sequencing and bioinformatics. Primary human DCs were treated with HSV-1 at MOI 10, IAV at MOI .5 and LPS (200 ng/ml) for 2 h. Cells were washed with cold PBS once and scraped. Pelleted cells were lysed in lysis buffer followed by RNA extraction according to manufacturer’s protocol (Biorad Auram Total RNA minikit, #731040). Hybrid-specific total RNA was depleted using an RNA library preparation kit with 1 µg of input RNA using the Truseq Stranded Total RNA Sample Prep Kit (Illumina, Cat#20020596) and sequenced on an Illumina HiSeq 2000. Poly-A RNA was purified using a Poly-A magnetic purification system. Poly-A RNA was fragmented using 5′ dTLinker followed by cDNA synthesis using random hexamers (5′ dTLinker-Mix). cDNA was purified using QIAquick PCR purification kit. cDNA was used for next-generation sequencing. NanoString analysis. Cell stimulation and RNA isolation was performed as described. The NanoString system was used for multiplex mRNA measurements using a custom 254 mRNA expression codeset against 250 proinflammatory, transcriptional, and functional markers. The data was normalized to the housekeeping gene GAPDH using a nCounter Digital Analyzer (Nanostring Technologies). RNA hybridization, data acquisition, and analysis was performed as per manufacturer’s specifications. RNA counts were processed to account for hybridization efficiency, and mRNA expressions across experimental groups were normalized to the geometric mean of six housekeeping genes. Chromatin immunoprecipitation. After stimulations, the cells were fixed with 1% formaldehyde, lysed, and sheared. The DNA was quantitated, and 5 mg of total chromatin was immunoprecipitated with specific antibodies and Dynabeads Protein A/G (Life Technologies #10004D). The DNA was then reverse cross-linked, purified, and quantitated by quantitative PCR (qPCR) amplification with primers designed at the promoter sites of the IFNB (F-5′-TGGTTGTGTCTCTTCGTTTCTC-3′, R-5′-CCCCCTTCTACCTTGGGAC-3′) and RSAD2 (F-5′-GCCGATGAGGACACCTCTTTCT-3′, R-5′-AAAGATGTCGCTTCCGTCCA-3′) genes for RNA Polymerase II and H3K4me3 ChIP. For STAT1 ChIP, primers targeting the STAT1 binding sites for CXCL10 (F-5′-AAAAAGAAGACCTGTCGCCGTA-3′), R-5′-CAGTCTGCTGCTTCTGGTCA-3′), RSAD2 (F-5′-TTGCCGCTTGTCAATCCTT-3′, R-5′-TCTGAGGACACCTCTTGGGAC-3′), IFI16 (F-5′-ATTTCGCATCCCTTCTTCTTC-3′, R-5′-GAAGATGTCGCTTCCGTCCA-3′), and MX2 (F-5′-ATCTTGTTGGGACACCTCTTTCT-3′, R-5′-CTGCTGCTGCTTCCGTCCA-3′) genes have been used. Antibodies used against were against RNA Polymerase II (RNA Pol II; Active Motif #39097), Histone H3 trimethylated at Lysine 4 (H3K4me3; Abcam # ab8081), STAT1 (Cell Signaling Technology, #9172), or control IgG isotype (Abcam # ab37415 or Cell Signaling Technology #5415) as per manufacturer’s recommended instructions. Data was calculated as the percentage fraction of total input DNA and using IgG isotype as a control. Nanoblasts. Nanoblasts were produced as described by Mangote, P. E. et al.22, HEK293T cells were plated at 70–80% confluency in a 10 cm dish in 10 ml of Glutamax DMEM with 10% FBS and 1% pen/strep. 0.3 µg VSV-G, 0.7 µg BRL, 2.7 µg 5349, 1.7 µg BicCar, 22 µg Blad for LUCAT1 sgRNA1, and 2.2 µg Blad for LUCAT1 sgRNA2 were transfected in HEK293T cells using JetPrime (Polyplus Transfection) according to the manufacturer’s instructions. VLP Nanoblade-containing supernatant was collected 40 h post transfection, centrifuged at 500 g for 5 min, and filtered using a 0.45 µm syringe filter to remove cells and debris. Nanoblasts were pelleted by ultracentrifugation at 35 000 rpm for 1.5 h and the pellet was resuspended in 100 µl of PBS. For LUCAT1 deletion, primary hDCs were plated in 12 well plates with 1.5 million cells per condition in 400 µl of hDC conditioned medium as described above. 40 µl of resuspended Nanoblasts were added per well and incubated at 37 °C for 4–5 h followed by centrifugation at 3500 × g for 5 min. The cells were incubated with Nanoblades for 48 h by stimulation and RNA/Protein analysis as described above. List of sequences are given in Supplementary Table 3.

**FISH and confocal microscopy.** Fluorescence In-Situ Hybridization (FISH) was carried out using ViewRNA FISH Cell Assay (Thermo Fisher) according to the manufacturer’s protocol. Primary human DC cells were incubated on coverslips in dishes with or without LPS stimulations. The cells were probed for LUCAT1.
Excise exon 1 of LUCAT1, a combination of two gRNAs (CloneTech, Cat#PT4421-2). 0.5×10^6 THP-1 cells were transduced using 5 µg/ml ART-1000. Post incubation, cells were washed and resuspended in 1 µg/µl concentration. Biotinylated RNAs were heated at 65 °C for 10 min and immediately placed on ice for 5 min. 100 µg of RNA was added to 100 µl of streptavidin beads and incubated at room temperature for 15 min. μMACS columns were used for recovery of streptavidin-biotin labeled RNA. μMACS columns were placed on magnetic stand and equilibrated using wash buffer before putting labeled RNA. After three subsequent washes, RNA was eluted using 100 µl of 100 mM DTT solution twice followed by EtOH precipitation. The resulting RNA was then analyzed for gene expression using RT-qPCR.

**References**

1. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* 472, 481–485 (2011).
2. Darnell, J. E. Jr., Kerr, I. M. & Stark, G. K. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264, 1451–21 (1994).
3. Ivashkov, L. B. & Donlin, L. T. Regulation of type I interferon responses. *Nat. Rev. Immunol.* 16, 293–322 (1998).
4. Mehta, A. & Baltimore, D. MicroRNAs as regulatory elements in immune system logic. *Nat. Rev. Immunol.* 16, 279–298 (2016).
5. Atianand, M. K., Caffrey, D. R. & Fitzgerald, K. A. Immunobiology of long noncoding RNAs. *Annu. Rev. Immunol.* 35, 177–198 (2017).
6. Derrien, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res.* 22, 1775–1789 (2012).
7. Hon, C. C. et al. An atlas of human long non-coding RNAs with accurate 5' ends. *Nature* 543, 199–204 (2017).
8. Ulltzy, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. *Cell* 154, 24–66 (2013).
9. Wang, K. C. & Chang, H. Y. Molecular mechanisms of long noncoding RNAs. *Nat. Rev. Cell. Biol.* 14, 187–196 (2013).
10. Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 464, 1071–1076 (2010).
11. Huard, T. M. Emerging role of lncRNAs in cancer. *Nat. Med.* 21, 1253–1261 (2015).
12. Arun, G. et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 IncRNA loss. *Genes Dev.* 30, 34–51 (2016).
13. Castellano-Rubio, A. et al. A long noncoding RNA associated with susceptibility to cell line biology. *Science* 352, 91–93 (2016).
14. Esteller, M. Non-coding RNAs in human disease. *Nat. Rev. Genet.* 12, 861–874 (2011).
15. Hennessy, E. J. et al. The long noncoding RNA CHROMK regulates cholesterol homeostasis in primate. *Nat. Metab.* 1, 98–110 (2019).
16. Carpenter, S. et al. A long noncoding RNA promotes activation and repression of immune response genes. *Science* 341, 789–92 (2013).
17. Li, Z. et al. The long noncoding RNA THRIL regulates TNFalpha expression through its interaction with hnrNPIL. *Proc. Natl Acad. Sci. USA* 111, 1002–1007 (2014).
18. Atianand, M. K. et al. A long noncoding RNA lncRNA-EPS acts as a transcriptional brake to restrain inflammation. *Cell* 165, 1672–1685 (2016).
19. Kotzin, J. J. et al. The long noncoding RNA MorbR regulates CD8 T cells in response to viral infection. *Proc. Natl Acad. Sci. USA* 116, 11916–11925 (2019).
20. Kotzin, J. J. et al. The long non-coding RNA MorbR regulates Bim and short-lived myeloid cell lifespan. *Nature* 537, 239–243 (2016).
21. Zhang, P. et al. The IncRNA Neat1 promotes activation of inflammasomes in macrophages. *Nat. Commun.* 10, 1495 (2019).
22. Thai, P. et al. Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines. *Am. J. Respir. Cell Mol. Biol.* 49, 204–211 (2013).
23. Zhang, L. et al. SPI-induced up-regulation of IncRNA LUCAT1 promotes proliferation, migration and invasion of cervical cancer by sponging miR-181a. *Artif. Cells Nanaomed. Biotechnol.* 47, 556–569 (2019).
24. Xiao, H. et al. Long non-coding RNA Lac1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma. *Oncotarget* 8, 113622–113634 (2017).
25. Yu, H. et al. Long noncoding RNA LUCAT1 promotes malignancy of ovarian cancer through regulation of miR-612/FOXA13 pathway. *Biochem Biophys. Res. Commun.* 503, 2095–2100 (2018).
26. Zheng, A. et al. Long noncoding RNA LUCAT1/miR-5852-3p/TCEB7 axis regulates breast cancer stemness via Wnt/beta-catenin pathway. *J. Exp. Clin. Cancer Res.* 38, 305 (2019).
28. Zhou, Q. et al. LUCA1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52. *Cancer Sci.* **110**, 1194–1207 (2019).

29. Rochet, E. et al. Expression of Long Non-Coding RNAs by Human Retinal Muller Glial Cells Infected with Clonal and Exotic Virulent Toxoplasma gondii. *Noncoding RNA* **5**, 48 (2019).

30. Gaidt, M. M. et al. Modeling primary human monocytes with the transdifferentiation cell line BlA2F1. *Methods Mol. Biol.* **1714**, 57–66 (2018).

31. Garibaldi, A., Carranza, F. & Hertel, K. J. Isolation of newly transcribed RNA using the metabolic label 4-Thiouridine. *Methods Mol. Biol.* **1648**, 169–176 (2017).

32. Mangeat, P. E. et al. Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with Cas9-sgRNA ribonucleoproteins. *Nat. Biotechnol.* **36**, 1027–1035 (2018).

33. Konermann, S. et al. Genome-scale transcripational activation by an engineered CRISPR-Cas9 complex. *Nature* **517**, 583–588 (2015).

34. Rinn, J. L. IncRNAs: linking RNA to chromatin. *Cold Spring Harb. Perspect. Biol.* **6**, a018614 (2014).

35. Geiser, S. & Coller, J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat. Rev. Mol. Cell Biol.* **14**, 699–712 (2013).

36. Tripathi, V. et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. *Mol. Cell** **39**, 925–938 (2010).

37. Chu, C. & Chang, H. Y. ChIP-MS: RNA-directed proteomic discovery. *Methods Mol. Biol.* **1861**, 37–45 (2018).

38. Hooks, J. J. et al. Immune interferon in the circulation of patients with autoimmune disease. *N. Engl. J. Med.* **301**, 5–8 (1979).

39. Skurkovich, S. V. et al. Lymphocytes’ cytotoxicity towards cells of human lymphoblastoid lines in patients with rheumatoid arthritis and systemic lupus erythematosus. *Ann. Allergy* **39**, 344–350 (1977).

40. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. *J. Biol. Chem.* **251**, 1861 – 1867 (1976).

41. Piganis, R. A. et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. *J. Biol. Chem.* **236**, 33811–33818 (2011).

42. Song, M. M. & Shuai, K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. *J. Biol. Chem.* **273**, 35056–35062 (1998).

43. You, M., Yu, D. H. & Feng, G. S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. *Mol. Cell Biol.* **19**, 2416–2424 (1999).

44. Francois-Newton, V. et al. USP18 establishes the transcriptional and antiproliferative interferon alpha/beta differential. *Biochem J.* **466**, 509–516 (2012).

45. Francois-Newton, V. et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. *PLoS ONE* **6**, e22200 (2011).

46. Kohanbash, G. & Okada, H. MicroRNAs and STAT interplay. *Semin. Cancer Biol.* **22**, 70–75 (2012).

47. Hou, J. et al. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. *J. Immunol.* **183**, 2130–2138 (2009).

48. Kambara, H. et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. *Nucleic Acids Res.* **42**, 10668–10680 (2014).

49. Li, P. et al. IncRNA SCAL1 inhibits inducible nitric oxide synthase in lung cells under high-glucose conditions. *Exp. Ther. Med.* **18**, 1831–1836 (2019).

50. Goff, L. A. & Rinn, J. L. Linking RNA biology to lncRNAs. *Nat. Rev. Mol. Cell Biol.* **25**, 1456–1465 (2015).

51. Carlevaro-Fita, J. & Johnson, R. Global positioning system: understanding long noncoding RNAs through subcellular localization. *Mol. Cell** **73**, 869–883 (2019).

52. Rapino, F. et al. C/EBP alpha induces highly efficient macrophage transdifferentiation of 8 lymphoma and leukemia cell lines and impairs their tumorigenicity. *Cell Rep.* **3**, 1153–1163 (2013).

53. Langmead, B. et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).

54. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *Bioinformatics* **12**, 323 (2011).

55. Leng, N. et al. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. *Bioinformatics* **29**, 1035–43 (2013).

56. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–11 (2009).

57. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* **28**, 511–515 (2010).

58. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).

**Acknowledgements**

This research is supported by U.S. Department of Health & Human Services, NIH, National Institute of Allergy and Infectious Diseases (NIAID) - AI167208; U.S. Department of Health & Human Services, NIH, National Institute of Allergy and Infectious Diseases (NIAID) - AI142231; U.S. Department of Health & Human Services, NIH, National Institute of Allergy and Infectious Diseases (NIAID) - AI067497; T.V. is supported by a research fellowship from the German Research Foundation (DFG, VI 1027/1-1).

**Author contributions**

S.A. and K.A.F designed research; S.A. and T.V. performed the experiment; S.G. performed RNA pol II and H3K4me3 ChIP experiments and Confocal imaging for FISH experiments; J.C. performed RNA seq sample prep on LPS-stimulated hDC; E.R. and Z.J. contributed new reagents/analytic tools; S.A. and T.V. analyzed data; R.K.K performed bioinformatics analysis and S.A., T.V., and K.A.F. wrote the paper.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-20165-5.

Correspondence and requests for materials should be addressed to K.A.F.

Peer review information *Nature communications* thanks Ram Savan and the other, anonymous reviewer(s) for their contribution to the peer review of this work. Peer review reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020